EGFR+ Lung Cancer

Frontline cetuximab plus FOLFIRI improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wildtype metastatic colorectal cancer.

The second-generation TKI dacomitinib, designed to treat NSCLC, is being evaluated in a clinical trial that will measure the drug’s effectiveness as a first-line treatment.

Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.

Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.

Data from the French National Cancer Institute showed an increase in testing for BRCA1/2 for breast and ovarian cancer, though not for the MMR mutation for Lynch syndrome.

Crizotinib demonstrated superiority to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement in a trial published online by The New England Journal of Medicine.

Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.

Cetuximab is an epidermal growth factor receptor inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.